IOT Innovotech Inc

Innovotech Inc. (TSX VENTURE:IOT), a leader in biofilm products, and TREK
Diagnostic Systems, a preeminent provider of diagnostic systems and
susceptibility products for microbiology labs, announced that TREK will
manufacture key components of Innovotech's novel biofilm susceptibility test at
TREK's Cleveland facility. Innovotech is targeting its initial product launch of
the bioFILM PA kit to the Canadian infectious-disease market.


Biofilms are estimated to cause more than 80 percent of all human infections and
are inherently resistant to antibiotics. Studies show that bacteria in a biofilm
may have a greater than 100-fold increase in resistance to antibiotics when
compared to the same bacteria in a planktonic (free-floating) state. Biofilms
are particularly dangerous for patients with chronic lung infections, such as
cystic fibrosis lung disease, and put patients with catheters, stents, and other
medical devices at risk of serious infection. They are also implicated in most
chronic hospital-borne infections.


Selecting the right drug at a dosage sufficient enough to completely kill the
bacteria is key to preventing resistance. Often doctors must prescribe a
cocktail of antibiotics to fight biofilm infections effectively, but there are
currently no dependable susceptibility tests to assist doctors in selecting
appropriate treatments. Innovotech's manual kit bioFILM PA will enable
clinicians to test biofilm samples against a combination of existing
antibiotics. Early results indicate that bioFILM PA will provide better
treatment outcomes for patients, improved infection-control for hospitals, and
substantial cost saving to health systems.


"The agreement will support initial production of bioFILM PA(TM) for the
Canadian market" says Dr. Bhavin Rawal, Product Manager, Innovotech. "TREK's
expertise in diagnostic in vitro susceptibility testing, its successful track
record with regulatory agencies, and its commitment to quality manufacturing at
its facilities in the US and UK are well known. In the future, we may also draw
on TREK's knowledge of the susceptibility market as we explore sales growth
outside of Canada and line expansion into other products."


According to TREK's Director of Laboratory Services, Cindy Knapp, this agreement
expands TREK's service offerings beyond custom susceptibility plates to
large-volume contract manufacturing. She commented, "At TREK, we are well-known
for our frozen and dried custom panels for clinical and pharmaceutical
customers. Now, we are proud to contribute our expertise in
susceptibility-products manufacturing to Innovotech's new bioFILM PA kit. Truly
an innovative design, the kit targets an important unmet need in the
susceptibility marketplace."


About Innovotech Inc: www.innovotech.ca

Innovotech is a product development company focusing on the development of
solutions to medical, agricultural and industrial problems caused by microbial
biofilms. Biofilms are protected communities of microorganisms which are very
common and very difficult to treat due to their inherent resistance. They have
been implicated in a host of devastating infections in agriculture, human health
and industry.


About TREK Diagnostic Systems: www.trekds.com

A Magellan Biosciences diagnostics company, TREK is a global manufacturer and
distributor of automated systems and consumable products for microbiology-based
diagnostic testing designed to improve patient outcomes. Signature product lines
include VersaTREK(R), Sensititre(R), Vizion(R), alamarBlue(R), para-JEM(R),
YeastOne(R), onSite(R) and TREK Lab Services. TREK is committed to delivering
the highest quality products and services to clinical, pharmaceutical, and
veterinary diagnostic laboratories worldwide.


This document contains forward-looking statements that are predictive in nature
and subject to risks and uncertainties that cannot be predicted or quantified;
consequently, actual results may differ materially from past results and those
expressed or implied by any forward-looking statements. Factors that could cause
or contribute to such risks or uncertainties include, but are not limited to:
the regulatory environment including the difficulty of predicting regulatory
outcomes; changes in the value of the Canadian dollar; the Company's reliance on
a small number of customers including government organizations; fluctuations in
operating results; government policies or actions; progress and cost of clinical
trials; reliance on key strategic relationships; uncertainty related to
intellectual property protection and potential costs associated with its
defense; the Company's exposure to lawsuits and other matters beyond the control
of management. Should known or unknown risks or uncertainties materialize, or
should management's assumptions prove inaccurate, actual results could vary
materially from those anticipated. The Company undertakes no obligation to
publicly make or update any forward-looking statements, except as required by
applicable law.

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jun 2024 to Jul 2024

Innovotech (TSXV:IOT)
Historical Stock Chart
From Jul 2023 to Jul 2024